Central and peripheral sites of action for CB2 receptor mediated analgesic activity in chronic inflammatory and neuropathic pain models in rats

Spinal Microglial and Perivascular Cell Cannabinoid Receptor Type 2 Activation Reduces Behavioral Hypersensitivity without Tolerance after Peripheral Nerve Injury

(2009) Alfonso Romero-Sandoval et al.   ANESTHESIOLOGY

Discovery of 1-[4-(3-Chlorophenylamino)-1-methyl-1H-pyrrolo[3,2-c]pyridin-7-yl]-1-morpholin-4-ylmethanone (GSK554418A), a Brain Penetrant 5-Azaindole CB2Agonist for the Treatment of Chronic Pain

(2009) Gerard M. P. Giblin et al.   JOURNAL OF MEDICINAL CHEMISTRY

Guide to Receptors and Channels (GRAC), 3rd edition

(2008) S P H Alexander et al.   BRITISH JOURNAL OF PHARMACOLOGY

Characterization of a Cannabinoid CB2 Receptor-Selective Agonist, A-836339 [2,2,3,3-Tetramethyl-cyclopropanecarboxylic Acid [3-(2-Methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], Using in Vitro Pharmacological Assays, in Vivo Pain Models, and Pharmacological Magnetic Resonance Imaging

(2008) B. B. Yao et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Cannabinoid CB2receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain

(2007) J Guindon et al.   BRITISH JOURNAL OF PHARMACOLOGY

In vitroandin vivocharacterization of A-796260: a selective cannabinoid CB2receptor agonist exhibiting analgesic activity in rodent pain models

(2007) B B Yao et al.   BRITISH JOURNAL OF PHARMACOLOGY

Cannabinoid CB2receptors in human brain inflammation

(2007) C Benito et al.   BRITISH JOURNAL OF PHARMACOLOGY

Species-specific in vitro pharmacological effects of the cannabinoid receptor 2 (CB2) selective ligand AM1241 and its resolved enantiomers

(2007) B Bingham et al.   BRITISH JOURNAL OF PHARMACOLOGY